Thr236
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr236  -  RSK4 (human)

Site Information
KAysFCGtVEyMAPE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2192798
Available spectra:  3 CST
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 )
Disease tissue studied:
luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , colorectal cancer ( 67 ) , colorectal carcinoma ( 67 ) , gastric cancer ( 17 , 18 , 19 , 20 , 30 , 31 , 32 , 33 , 34 , 35 , 38 , 41 , 42 , 43 , 48 , 50 , 52 , 59 , 60 , 64 ) , gastric carcinoma ( 17 , 18 , 19 , 20 , 30 , 31 , 32 , 33 , 34 , 35 , 38 , 41 , 42 , 43 , 48 , 50 , 52 , 59 , 60 , 64 ) , leukemia ( 63 ) , chronic myelogenous leukemia ( 63 ) , lung cancer ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 36 , 37 , 39 , 40 , 44 , 45 , 46 , 47 , 49 , 57 , 58 , 61 , 67 ) , non-small cell lung cancer ( 5 , 6 , 7 , 9 , 10 , 11 , 12 , 36 , 37 , 39 , 40 , 44 , 45 , 46 , 47 , 49 , 58 , 61 ) , non-small cell lung adenocarcinoma ( 5 , 6 , 7 , 8 , 9 , 10 , 11 , 36 , 39 , 40 , 44 , 45 , 46 , 47 , 49 ) , non-small cell large cell lung carcinoma ( 6 , 9 ) , non-small cell squamous cell lung carcinoma ( 8 , 36 , 39 , 40 ) , small-cell lung cancer ( 3 , 4 ) , lymphoma ( 2 ) , Burkitt's lymphoma ( 2 ) , follicular lymphoma ( 2 ) , mantle cell lymphoma ( 2 ) , melanoma skin cancer ( 54 , 55 , 56 )
Relevant cell line - cell type - tissue:
A498 (renal) ( 53 ) , A549 (pulmonary) ( 5 , 67 ) , BJAB (B lymphocyte) ( 2 ) , breast ( 1 ) , Cal-12T (pulmonary) ( 11 ) , Calu-3 (pulmonary) ( 7 ) , DMS153 (pulmonary) ( 10 ) , DMS53 (pulmonary) ( 4 ) , DMS79 (pulmonary) ( 3 ) , FL-318 (B lymphocyte) ( 2 ) , HCC15 (pulmonary) ( 8 ) , HCC44 (pulmonary) ( 11 ) , HCC78 (pulmonary) ( 9 ) , HCC827 (pulmonary) ( 7 ) , HCT116 (intestinal) ( 67 ) , HeLa (cervical) ( 29 , 65 ) , HeLa_Meta (cervical) ( 51 ) , HeLa_Pro (cervical) ( 51 ) , HeLa_Telo (cervical) ( 51 ) , JEKO-1 (B lymphocyte) ( 2 ) , Jurkat (T lymphocyte) ( 27 , 28 , 62 , 67 ) , K562 (erythroid) ( 63 ) , KATO III (gastric) ( 64 ) , LOU-NH91 (squamous) ( 8 ) , lung ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 57 , 58 , 61 ) , MKN-45 (gastric) ( 13 , 17 , 18 , 19 , 20 , 30 , 31 , 32 , 33 , 34 , 35 , 38 , 41 , 42 , 43 , 48 , 50 , 52 , 59 , 60 ) , NCI-H128 (pulmonary) ( 3 ) , NCI-H1299 (pulmonary) ( 6 ) , NCI-H1355 (pulmonary) ( 5 ) , NCI-H1417 (pulmonary) ( 3 ) , NCI-H1437 (pulmonary) ( 10 , 11 ) , NCI-H1650 (pulmonary) ( 7 ) , NCI-H1666 (pulmonary) ( 11 ) , NCI-H1703 (squamous) ( 8 , 13 , 36 , 39 , 40 ) , NCI-H1734 (pulmonary) ( 6 ) , NCI-H1781 (pulmonary) ( 9 ) , NCI-H1792 (pulmonary) ( 5 ) , NCI-H1944 (pulmonary) ( 6 ) , NCI-H1975 (pulmonary) ( 7 ) , NCI-H2073 (pulmonary) ( 8 , 10 ) , NCI-H209 (pulmonary) ( 3 , 10 ) , NCI-H2106 (pulmonary) ( 7 ) , NCI-H2228 (pulmonary) ( 9 ) , NCI-H23 (pulmonary) ( 5 ) , NCI-H2342 (pulmonary) ( 8 ) , NCI-H2405 (pulmonary) ( 11 ) , NCI-H3122 (pulmonary) ( 9 , 12 ) , NCI-H3255 (pulmonary) ( 13 , 37 ) , NCI-H358 (pulmonary) ( 6 ) , NCI-H441 (pulmonary) ( 5 , 44 , 45 , 46 , 47 , 49 ) , NCI-H446 (pulmonary) ( 4 ) , NCI-H460 (pulmonary) ( 6 ) , NCI-H524 (pulmonary) ( 3 ) , NCI-H526 (pulmonary) ( 4 ) , NCI-H661 (pulmonary) ( 9 ) , NCI-H69 (pulmonary) ( 4 ) , NCI-H82 (pulmonary) ( 4 ) , NCI-H838 (pulmonary) ( 10 ) , Raji (B lymphocyte) ( 2 ) , RAMOS (B lymphocyte) ( 2 ) , REC-1 (B lymphocyte) ( 2 ) , skin ( 54 , 55 , 56 )

Upstream Regulation
Treatments:
MG132_withdrawal ( 51 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

7

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

8

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

9

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

10

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

11

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

12

Rikova K (2013) CST Curation Set: 18459; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

13

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

14

Rikova K (2012) CST Curation Set: 13733; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 2/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

15

Rikova K (2012) CST Curation Set: 13732; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 1/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

16

Rikova K (2012) CST Curation Set: 13734; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 3/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

17

Mulhern D (2012) CST Curation Set: 13402; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

18

Mulhern D (2012) CST Curation Set: 13405; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

19

Mulhern D (2012) CST Curation Set: 13458; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

20

Mulhern D (2012) CST Curation Set: 13459; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

21

Rikova K (2011) CST Curation Set: 13125; Year: 2011; Biosample/Treatment: cell line, MGH-3/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

22

Rikova K (2011) CST Curation Set: 13126; Year: 2011; Biosample/Treatment: cell line, MGH-4/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

23

Rikova K (2011) CST Curation Set: 13127; Year: 2011; Biosample/Treatment: cell line, MGH-5/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

24

Rikova K (2011) CST Curation Set: 13129; Year: 2011; Biosample/Treatment: cell line, MGH-7/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

25

Rikova K (2011) CST Curation Set: 13131; Year: 2011; Biosample/Treatment: cell line, MGH-9/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

26

Rikova K (2011) CST Curation Set: 13132; Year: 2011; Biosample/Treatment: cell line, MGH-10/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

27

Mulhern D (2011) CST Curation Set: 13072; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

28

Guo A (2011) CST Curation Set: 11885; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

29

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

30

Moritz A (2010) CST Curation Set: 10603; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

31

Moritz A (2010) CST Curation Set: 10602; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

32

Moritz A (2010) CST Curation Set: 10609; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

33

Moritz A (2010) CST Curation Set: 10607; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

34

Moritz A (2010) CST Curation Set: 10610; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

35

Moritz A (2010) CST Curation Set: 10613; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

36

Moritz A (2010) CST Curation Set: 10594; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

37

Moritz A (2010) CST Curation Set: 10598; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

38

Moritz A (2010) CST Curation Set: 10600; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

39

Moritz A (2010) CST Curation Set: 10595; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

40

Moritz A (2010) CST Curation Set: 10596; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

41

Moritz A (2010) CST Curation Set: 10232; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

42

Moritz A (2010) CST Curation Set: 10236; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

43

Moritz A (2010) CST Curation Set: 10231; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

44

Moritz A (2010) CST Curation Set: 9985; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

45

Moritz A (2010) CST Curation Set: 9984; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

46

Moritz A (2010) CST Curation Set: 9983; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

47

Moritz A (2010) CST Curation Set: 9986; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

48

Moritz A (2010) CST Curation Set: 10022; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

49

Moritz A (2010) CST Curation Set: 9980; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

50

Moritz A (2010) CST Curation Set: 10023; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

51

Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81
20097925   Curated Info

52

Moritz A (2010) CST Curation Set: 9923; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

53

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

54

Tucker M (2010) CST Curation Set: 9778; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

55

Tucker M (2010) CST Curation Set: 9782; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

56

Tucker M (2010) CST Curation Set: 9785; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

57

Rikova K (2010) CST Curation Set: 9451; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

58

Rikova K (2010) CST Curation Set: 9468; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

59

Moritz A (2010) CST Curation Set: 9279; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'||' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

60

Moritz A (2010) CST Curation Set: 9234; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

61

Rikova K (2010) CST Curation Set: 9215; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

62

Moritz A (2010) CST Curation Set: 8838; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

63

Moritz A (2010) CST Curation Set: 8837; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

64

Possemato A (2009) CST Curation Set: 8414; Year: 2009; Biosample/Treatment: cell line, KATO III/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

65

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

66

Gu T (2007) CST Curation Set: 2563; Year: 2007; Biosample/Treatment: cell line, RSK-10/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

67

Wissing J, et al. (2007) Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Mol Cell Proteomics 6, 537-47
17192257   Curated Info

68

Gu T (2007) CST Curation Set: 2462; Year: 2007; Biosample/Treatment: cell line, RSK2-5/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

69

Gu T (2007) CST Curation Set: 2465; Year: 2007; Biosample/Treatment: cell line, RSK2-8/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info